Surgical androgen suppression less costly in prostate cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.304, 2001-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Degarelix less costly than goserelin for prostate cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 642, 2011-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Androgen suppression improves survival in prostate cancer

Inpharma, Vol. 1, Iss. 1622, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Adjuvant androgen suppression improves survival in prostate cancer

Inpharma, Vol. 1, Iss. 1452, 2004-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Androgen suppression beneficial in prostate cancer?

Inpharma, Vol. 1, Iss. 1256, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Androgen deprivation therapy for prostate cancer

By Singer Eric A Golijanin Dragan J Miyamoto Hiroshi Messing Edward M

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 2, 2008-02 ,pp. : 211-228

Informa Healthcare

Access to resources Recommend Favorite